Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in retinal ganglion cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 214 | 0.85 |
| pathways Reactome | 2 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 12700
Sealed predictions
- SYN2 in dopamine neurons, braak+0.28 (p 0.459) → +0.67 (p 0.049)receipt 12706
Swarm cases
receipt 12706: SYN2 in dopamine neurons, braak
- power
- full sample +0.44 (p 0.066, n 18), 95% CI -0.03 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.49 (p 0.041, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.41 (p 0.091, n 18). could be the mix.
- skeptic
- leave-one-out range +0.35 to +0.60, sign flips 0; without severely affected donors +0.44 (p 0.066, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SYN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts